Can Fite Biopharma Net Income
| CANF Stock | USD 4.21 0.10 2.32% |
As of the 19th of February, Can Fite shows the Standard Deviation of 7.21, mean deviation of 5.14, and Risk Adjusted Performance of (0.06). Can Fite Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Can Fite Biopharma variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Can Fite Biopharma is priced correctly, providing market reflects its regular price of 4.21 per share. Given that Can Fite has information ratio of (0.09), we suggest you to validate Can Fite Biopharma's prevailing market performance to make sure the company can sustain itself at a future point.
Can Fite Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 14.0998 | Revenue | Quarterly Revenue Growth (0.36) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -7.1 M | -7.4 M | |
| Net Loss | -9.1 M | -9.5 M | |
| Net Loss | -11.7 M | -12.3 M | |
| Net Income Per E B T | 0.90 | 0.78 |
Can | Net Income | Build AI portfolio with Can Stock |
The Net Income trend for Can Fite Biopharma offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Can Fite is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Can Fite's Net Income Growth Pattern
Below is the plot of the Net Income of Can Fite Biopharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Can Fite Biopharma financial statement analysis. It represents the amount of money remaining after all of Can Fite Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Can Fite's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Can Fite's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (7.88 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Can Net Income Regression Statistics
| Arithmetic Mean | (7,857,583) | |
| Coefficient Of Variation | (38.00) | |
| Mean Deviation | 2,232,344 | |
| Median | (7,092,000) | |
| Standard Deviation | 2,985,823 | |
| Sample Variance | 8.9T | |
| Range | 10.8M | |
| R-Value | (0.44) | |
| Mean Square Error | 7.7T | |
| R-Squared | 0.19 | |
| Significance | 0.08 | |
| Slope | (259,517) | |
| Total Sum of Squares | 142.6T |
Can Net Income History
Other Fundumenentals of Can Fite Biopharma
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Can Fite Net Income component correlations
Can Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Can Fite is extremely important. It helps to project a fair market value of Can Stock properly, considering its historical fundamentals such as Net Income. Since Can Fite's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Can Fite's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Can Fite's interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Can have expansion opportunities? Factors like these will boost the valuation of Can Fite. Projected growth potential of Can fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Can Fite demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding Can Fite Biopharma requires distinguishing between market price and book value, where the latter reflects Can's accounting equity. The concept of intrinsic value - what Can Fite's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Can Fite's price substantially above or below its fundamental value.
It's important to distinguish between Can Fite's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Can Fite should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Can Fite's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Can Fite 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Can Fite's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Can Fite.
| 11/21/2025 |
| 02/19/2026 |
If you would invest 0.00 in Can Fite on November 21, 2025 and sell it all today you would earn a total of 0.00 from holding Can Fite Biopharma or generate 0.0% return on investment in Can Fite over 90 days. Can Fite is related to or competes with Kazia Therapeutics, CNS Pharmaceuticals, Clearmind Medicine, Soligenix, GRI Bio, Oragenics, and Silo Pharma. Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for th... More
Can Fite Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Can Fite's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Can Fite Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 38.42 | |||
| Value At Risk | (8.59) | |||
| Potential Upside | 10.4 |
Can Fite Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Can Fite's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Can Fite's standard deviation. In reality, there are many statistical measures that can use Can Fite historical prices to predict the future Can Fite's volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.57) | |||
| Total Risk Alpha | (0.96) | |||
| Treynor Ratio | 0.3932 |
Can Fite February 19, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | 0.4032 | |||
| Mean Deviation | 5.14 | |||
| Coefficient Of Variation | (1,163) | |||
| Standard Deviation | 7.21 | |||
| Variance | 51.97 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.57) | |||
| Total Risk Alpha | (0.96) | |||
| Treynor Ratio | 0.3932 | |||
| Maximum Drawdown | 38.42 | |||
| Value At Risk | (8.59) | |||
| Potential Upside | 10.4 | |||
| Skewness | (0.19) | |||
| Kurtosis | 2.36 |
Can Fite Biopharma Backtested Returns
Can Fite Biopharma secures Sharpe Ratio (or Efficiency) of -0.0331, which signifies that the company had a -0.0331 % return per unit of risk over the last 3 months. Can Fite Biopharma exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Can Fite's Standard Deviation of 7.21, mean deviation of 5.14, and Risk Adjusted Performance of (0.06) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -1.6, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Can Fite are expected to decrease by larger amounts. On the other hand, during market turmoil, Can Fite is expected to outperform it. At this point, Can Fite Biopharma has a negative expected return of -0.24%. Please make sure to confirm Can Fite's skewness, and the relationship between the total risk alpha and day median price , to decide if Can Fite Biopharma performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.1 |
Very weak reverse predictability
Can Fite Biopharma has very weak reverse predictability. Overlapping area represents the amount of predictability between Can Fite time series from 21st of November 2025 to 5th of January 2026 and 5th of January 2026 to 19th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Can Fite Biopharma price movement. The serial correlation of -0.1 indicates that less than 10.0% of current Can Fite price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.1 | |
| Spearman Rank Test | 0.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Can Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Can Fite Biopharma reported net income of (7.88 Million). This is 102.31% lower than that of the Biotechnology sector and 111.25% lower than that of the Health Care industry. The net income for all United States stocks is 101.38% higher than that of the company.
Can Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Can Fite's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Can Fite could also be used in its relative valuation, which is a method of valuing Can Fite by comparing valuation metrics of similar companies.Can Fite is currently under evaluation in net income category among its peers.
Can Fite Current Valuation Drivers
We derive many important indicators used in calculating different scores of Can Fite from analyzing Can Fite's financial statements. These drivers represent accounts that assess Can Fite's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Can Fite's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 65.1B | 51.5B | 28.5B | 34.0B | 39.2B | 37.2B | |
| Enterprise Value | 65.1B | 51.5B | 28.5B | 34.0B | 39.1B | 72.8B |
Can Fite ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Can Fite's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Can Fite's managers, analysts, and investors.Environmental | Governance | Social |
Can Fundamentals
| Return On Equity | -2.64 | ||||
| Return On Asset | -0.82 | ||||
| Operating Margin | (24.25) % | ||||
| Current Valuation | (641.14 K) | ||||
| Shares Outstanding | 17.07 M | ||||
| Shares Owned By Institutions | 5.53 % | ||||
| Number Of Shares Shorted | 51.4 K | ||||
| Price To Earning | (3.41) X | ||||
| Price To Book | 1.42 X | ||||
| Price To Sales | 10.08 X | ||||
| Revenue | 674 K | ||||
| Gross Profit | 560 K | ||||
| EBITDA | (8.12 M) | ||||
| Net Income | (7.88 M) | ||||
| Cash And Equivalents | 12.77 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 104 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.78 X | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (7.64 M) | ||||
| Short Ratio | 0.19 X | ||||
| Target Price | 3.5 | ||||
| Beta | 0.042 | ||||
| Market Capitalization | 15.24 M | ||||
| Total Asset | 9.12 M | ||||
| Retained Earnings | (166.36 M) | ||||
| Working Capital | 6.93 M | ||||
| Current Asset | 39.51 M | ||||
| Current Liabilities | 5.77 M | ||||
| Net Asset | 9.12 M |
About Can Fite Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Can Fite Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Can Fite using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Can Fite Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Can Biotechnology industry sustain growth momentum? Does Can have expansion opportunities? Factors like these will boost the valuation of Can Fite. Projected growth potential of Can fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Can Fite demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding Can Fite Biopharma requires distinguishing between market price and book value, where the latter reflects Can's accounting equity. The concept of intrinsic value - what Can Fite's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Can Fite's price substantially above or below its fundamental value.
It's important to distinguish between Can Fite's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Can Fite should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Can Fite's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.